Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest glioblastoma multiforme Stories

2013-04-08 12:27:56

BETHESDA, Md., April 8, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, filed its annual report on Form 10K today, reporting its financial results for the year ended December 31, 2012. The report also shows strong progress in all areas of the Company's operations, enhancing the Company's leadership position in immune therapies for cancer. (Logo:...

2013-04-05 12:24:40

Neurosurgeons find new treatment for glioblastoma safe; opens door for larger study CLEVELAND, April 5, 2013 /PRNewswire/ -- The first-in-human study of the NeuroBlate(TM) Thermal Therapy System finds that it appears to provide a new, safe and minimally invasive procedure for treating recurrent glioblastoma (GBM), a malignant type of brain tumor. The study, which appears April 5 in the Journal of Neurosurgery online, was written by lead author Andrew Sloan, MD, director of...

2013-04-01 12:25:48

VANCOUVER, British Columbia and MENLO PARK, Calif., April 1, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the company would present an abstract entitled "A Phase I/II study of VAL-083 in patients with recurrent malignant glioma or secondary brain tumor" at the American Association of Cancer Research (AACR) Annual Meeting, which is being held April 6 - 10, 2013 in Washington D.C., USA. DelMar will present new clinical data from its ongoing...

2013-03-19 08:27:17

CEO Will Discuss Key Strengths and Progress, Announce New Developments BETHESDA, Md., March 19, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that Linda F. Powers, the Company's Chairman and Chief Executive Officer, will be presenting at the 25(th) Annual ROTH Conference at 8:30 a.m. PDT on Wednesday, March 20, 2013, at the Ritz-Carlton,...

2013-03-13 13:43:58

Johns Hopkins researchers use a type of stem cells from human adipose tissue to chase migrating cancer cells In laboratory studies, Johns Hopkins researchers say they have found that stem cells from a patient's own fat may have the potential to deliver new treatments directly into the brain after the surgical removal of a glioblastoma, the most common and aggressive form of brain tumor. The investigators say so-called mesenchymal stem cells (MSCs) have an unexplained ability to seek out...

2013-03-12 08:29:45

Approvals Expanding the Scope of German Manufacturing Are Key Steps BETHESDA, Md., March 12, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that the Company has taken a key step in building Europe-wide arrangements for manufacturing and distribution of DCVax. This represents a major area of competitive differentiation and strength for NW...

2013-03-11 23:02:40

Girl´s Night Out Event is to honor those affected by brain tumors and brain cancer. All proceeds from the night and weekend will go directly to the Chris Elliott Fund. Seattle, WA (PRWEB) March 11, 2013 The Chris Elliott Fund (CEF) is pleased to announce the Girls Night Out benefit event on Thursday March 21st from 5-8pm, in Woodinville, Washington. The event is in partnership with glassybaby, Woodinville-based winery JM Cellars, and Butler Valet. All of the night´s wine and...

2013-03-07 08:29:48

BETHESDA, Md., March 7, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that it expects to complete enrollment in its 312-patient Phase III clinical trial for Glioblastoma multiforme (GBM) brain cancer within a period that is faster or more efficient than relevant comparison trials with immune therapies for the same brain cancer. The...

2013-03-07 08:29:18

Booke & Co. to Provide Investor Relations Counsel VANCOUVER, British Columbia and MENLO PARK, Calif., March 7, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the completion of a $10.5 million private placement. Charles Vista, LLC acted as the company's placement agent in the unit offering. Each unit consists of one share of common stock and one common stock purchase warrant. The maximum offering in the Private Placement consisted of...

2013-03-05 23:04:41

Scientists at Duke and Johns Hopkins found mutations in two genes that could become therapeutic targets in malignant glioma. Could this be the research breakthrough in the type of pediatric brain stem tumor that children must face? (PRWEB) March 05, 2013 The Rory David Deutsch Foundation wants you to know that there are many “heroes” in the fight to eradicate pediatric brain cancer. The children at the center of the battle lead the way. The scientists who put in long hours of...